VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab

David P. Carbone, J. Stuart Salmon, David D Billheimer, Heidi Chen, Alan Sandler, Heinrich Roder, Joanna Roder, Maxim Tsypin, Roy S. Herbst, Anne S. Tsao, Hai T. Tran, Thao P. Dang

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat®) in a blinded manner to pretreatment sera obtained from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus bevacizumab. We found that VeriStrat® could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen.

Original languageEnglish (US)
Pages (from-to)337-340
Number of pages4
JournalLung Cancer
Volume69
Issue number3
DOIs
StatePublished - Sep 2010
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Survival
Poisons
Serum
Proteomics
Patient Selection
Therapeutics
Bevacizumab
Erlotinib Hydrochloride

Keywords

  • Bevacizumab
  • Erlotinib
  • Lung cancer
  • Personalized therapy
  • Proteomics
  • Serum biomarker

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Medicine(all)

Cite this

VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. / Carbone, David P.; Salmon, J. Stuart; Billheimer, David D; Chen, Heidi; Sandler, Alan; Roder, Heinrich; Roder, Joanna; Tsypin, Maxim; Herbst, Roy S.; Tsao, Anne S.; Tran, Hai T.; Dang, Thao P.

In: Lung Cancer, Vol. 69, No. 3, 09.2010, p. 337-340.

Research output: Contribution to journalArticle

Carbone, DP, Salmon, JS, Billheimer, DD, Chen, H, Sandler, A, Roder, H, Roder, J, Tsypin, M, Herbst, RS, Tsao, AS, Tran, HT & Dang, TP 2010, 'VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab', Lung Cancer, vol. 69, no. 3, pp. 337-340. https://doi.org/10.1016/j.lungcan.2009.11.019
Carbone, David P. ; Salmon, J. Stuart ; Billheimer, David D ; Chen, Heidi ; Sandler, Alan ; Roder, Heinrich ; Roder, Joanna ; Tsypin, Maxim ; Herbst, Roy S. ; Tsao, Anne S. ; Tran, Hai T. ; Dang, Thao P. / VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. In: Lung Cancer. 2010 ; Vol. 69, No. 3. pp. 337-340.
@article{0aef116ecb4b42959ea9dca939541678,
title = "VeriStrat{\circledR} classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab",
abstract = "We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat{\circledR}) in a blinded manner to pretreatment sera obtained from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus bevacizumab. We found that VeriStrat{\circledR} could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen.",
keywords = "Bevacizumab, Erlotinib, Lung cancer, Personalized therapy, Proteomics, Serum biomarker",
author = "Carbone, {David P.} and Salmon, {J. Stuart} and Billheimer, {David D} and Heidi Chen and Alan Sandler and Heinrich Roder and Joanna Roder and Maxim Tsypin and Herbst, {Roy S.} and Tsao, {Anne S.} and Tran, {Hai T.} and Dang, {Thao P.}",
year = "2010",
month = "9",
doi = "10.1016/j.lungcan.2009.11.019",
language = "English (US)",
volume = "69",
pages = "337--340",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab

AU - Carbone, David P.

AU - Salmon, J. Stuart

AU - Billheimer, David D

AU - Chen, Heidi

AU - Sandler, Alan

AU - Roder, Heinrich

AU - Roder, Joanna

AU - Tsypin, Maxim

AU - Herbst, Roy S.

AU - Tsao, Anne S.

AU - Tran, Hai T.

AU - Dang, Thao P.

PY - 2010/9

Y1 - 2010/9

N2 - We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat®) in a blinded manner to pretreatment sera obtained from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus bevacizumab. We found that VeriStrat® could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen.

AB - We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat®) in a blinded manner to pretreatment sera obtained from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus bevacizumab. We found that VeriStrat® could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen.

KW - Bevacizumab

KW - Erlotinib

KW - Lung cancer

KW - Personalized therapy

KW - Proteomics

KW - Serum biomarker

UR - http://www.scopus.com/inward/record.url?scp=77955095255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955095255&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2009.11.019

DO - 10.1016/j.lungcan.2009.11.019

M3 - Article

C2 - 20036440

AN - SCOPUS:77955095255

VL - 69

SP - 337

EP - 340

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -